Chinese neurotechnology firm BrainCo is developing a wearable device that it says could suppress appetite by stimulating the brain, positioning it as a potential non-drug alternative to blockbuster GLP-1 weight-loss treatments.

The Trump administration is seeking to restrict American investment in Chinese biotechnology companies, potentially complicating financial ties at a time when US drugmakers are increasingly turning to China for new medicines.

Novartis AG will license a messenger RNA-based autoimmune therapy from China’s Abogen Biosciences, in a deal worth as much as $7.8 billion.

An experimental lung disease drug developed using artificial intelligence showed promise in reversing biological signs of aging, pointing to broader potential use of the treatment, according to its developer.

The Pentagon’s designation of WuXi AppTec Co. as a Chinese military company may have prompted some US clients to pull back, but investors are still piling into the stock betting the firm will remain central to the global supply of obesity, cancer and other drugs.

Prices of lab monkeys in China have surged, complicating new drug development trials and increasing the need for primate imports from neighboring countries.

President Donald Trump’s threat of 100% tariffs against generic medicines is a major expansion of a strategy he’s been using against the pharmaceutical industry since his second term began.

Generic drug manufacturers must move production to the US or face a 100% import duty from August 2028, President Donald Trump said, threatening the supply of low-cost medicines that millions of Americans rely on.

Axiom Biosciences is considering an initial public offering in Hong Kong, a rare move for an American biotechnology firm, and one that would help it tap China’s booming clinical development capabilities.

The brain has emerged as a new frontier in medical technology. Bloomberg Primer explores where the next neurotechnology advances will lead. 

Shares of Metis TechBio Co, a biotechnology company using artificial intelligence to deliver and formulate drugs, jumped 127% in their Hong Kong debut on Wednesday, adding to a string of first-day pops in the city.

Bristol-Myers Squibb Co. inked a collaboration and licensing deal with Jiangsu Hengrui Pharmaceuticals Co. that could be valued at as much as $15.2 billion, as the US drugmaker seeks to leverage China’s efficiency in early development.

CSL Ltd. plunged the most on record after the Australian biotechnology company cut its full-year outlook and flagged about $5 billion in additional impairments, warning a turnaround will take longer than expected following a review by its interim chief executive.

Innovent Biologics Inc. shares saw their biggest gains in nearly five months, after the Chinese drugmaker posted its first annual profit thanks to surging demand for its weight-loss drug.

China has approved its first-ever invasive brain-computer interface product, marking a key regulatory milestone in Chinese startups’ quest to challenge US rivals such as Elon Musk-backed Neuralink Corp. in the cutting-edge field.

Earendil Labs, a biotechnology startup that uses artificial intelligence for drug discovery, is considering listing in Hong Kong, according to people familiar with the matter.

Eli Lilly & Co will invest $3 billion in China over the next decade to expand local production, with a focus on weight loss as the US drugmaker looks to cement its dominance in the booming obesity market.

Haleon PLC is making a 65 million pound ($87.2 million) investment in a new oral health plant in Shanghai, as the consumer health giant doubles down on markets like China and India to drive growth.

China has approved a new obesity treatment from Pfizer Inc., heightening competition in a market poised to become even more crowded with the looming entry of generics.

Chinese biotechnology firm MGI Tech Co. announced it will divest its wholly-owned US subsidiary, Complete Genomics Inc, retreating from a decade-long quest to expand in the American market amid what it described as an increasingly grim policy environment.